

NEW YORK, Oct. 2, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

[PharmaPoint: Alzheimer's Disease - China Drug Forecast and Market Analysis to 2022](http://www.reportlinker.com/p01658537/PharmaPoint-Alzheimer's-Disease---China-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology)

http://www.reportlinker.com/p01658537/PharmaPoint-Alzheimer's-Disease---China-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Alzheimer's Disease - China Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, "PharmaPoint: Alzheimer's Disease - China Drug Forecast and Market Analysis to 2022". There are no long-term effective therapies for Alzheimer's Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.

Being the most populated nation in the world and having a government with ample resources, China could potentially observe astounding AD drug growth during the forecast period. Unfortunately, we do not envision this to occur within the next 10 years due to China's acceptance of its underdeveloped healthcare infrastructure. The lack of access to healthcare in

rural parts of the nation, the limited provision of social services, and limited efforts to maintain adequate public health suggest that there are many areas that require significant changes before the topic of AD can be properly addressed.

Scope - Overview of Alzheimer's Disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in China from 2012-2022.

- Analysis of the impact of key events as well the drivers and restraints affecting China Alzheimer's Disease market.

Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for Alzheimer's Disease

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of drug performance

- Obtain sales forecast for drugs from 2012-2022 in China

Table of Contents

1	Table of Contents	51.1	List of Tables	81.2	List of Figures	92	Introduction	102.1	Catalyst	102.2	Related Reports	113	Disease Overview	133.1	Etiology and Pathophysiology	143.1.1	Etiology	143.1.2	Pathophysiology	173.2	Symptoms	294	Disease Management	314.1	Diagnosis	314.1.1	Probable Alzheimer's Disease Dementia	324.1.2	Possible AD Dementia	334.1.3	Probable AD Dementia with Evidence of AD Pathophysiological Process	334.1.4	Possible Alzheimer's Dementia with Evidence of the Alzheimer's Disease Pathophysiological Process	344.1.5	Preclinical AD	344.1.6	Mild Cognitive Impairment	354.2	Treatment Overview	374.3	China	404.3.1	Diagnosis	404.3.2	Clinical Practice	405	Competitive Assessment	425.1	Overview	425.2	Strategic Competitor Assessment	425.3	Product Profiles - Major Brands	455.3.1	Aricept (donepezil hydrochloride)	455.3.2	Exelon (rivastigmine, rivastigmine tartrate)	495.3.3	Razadyne (galantamine hydrobromide)	545.3.4	Namenda (memantine hydrochloride)	586	Opportunity and Unmet Need	626.1	Unmet Needs Overview	626.1.1	Public Awareness	646.1.2	Specialized Institutions at Local Levels	656.1.3	Screening and Diagnosis	656.1.4	Early Intervention	666.1.5	Improved Clinical Trial Design	676.1.6	Effective Therapy	686.1.7	Behavioral Treatments	696.2	Gap Analysis	696.2.1	Disease Prevention	706.2.2	Diagnosis from Biomarkers	716.2.3	Behavioral Therapies	727	Pipeline Assessment	737.1	Overview	737.2	Early-Stage Pipeline Assessment	737.3	AD Pipeline by Mechanism of Action	757.4	Enzymatic Processing	767.5	Immunization	777.6	Anti-Aggregation	777.7	"Me-Too"	787.8	Novel Therapeutic Approaches	797.9	Technology Trends	797.10	Promising Drugs in Clinical Development	808	Market Outlook	828.1	China	828.1.1	Forecast	828.1.2	Key Events	858.1.3	Drivers and Barriers	859	Appendix	879.1	Bibliography	879.2	Abbreviations	989.3	Methodology	1049.4	Forecasting Methodology	1049.4.1	Diagnosed AD patients	1049.4.2	Percent Drug-treated Patients	1059.4.3	Drugs Included in Each Therapeutic Class	1059.4.4	General Pricing Assumptions	1069.4.5	Individual Drug Assumptions	1069.4.6	Generic Erosion	1089.5	Physicians and Specialists Included in this Study	1089.6	About the Authors	1099.6.1	Author	1099.6.2	Global Head of Healthcare	1109.7	About GlobalData	1119.8	Disclaimer	111
---	-------------------	------	----------------	------	-----------------	----	--------------	-------	----------	-------	-----------------	-----	------------------	-------	------------------------------	---------	----------	---------	-----------------	-------	----------	-----	--------------------	-------	-----------	---------	---------------------------------------	---------	----------------------	---------	---	---------	---	---------	----------------	---------	---------------------------	-------	--------------------	-------	-------	---------	-----------	---------	-------------------	-----	------------------------	-------	----------	-------	---------------------------------	-------	---------------------------------	---------	-----------------------------------	---------	--	---------	-------------------------------------	---------	-----------------------------------	-----	----------------------------	-------	----------------------	---------	------------------	---------	--	---------	-------------------------	---------	--------------------	---------	--------------------------------	---------	-------------------	---------	-----------------------	-------	--------------	---------	--------------------	---------	---------------------------	---------	----------------------	-----	---------------------	-------	----------	-------	---------------------------------	-------	------------------------------------	-------	----------------------	-------	--------------	-------	------------------	-------	----------	-------	------------------------------	-------	-------------------	--------	---	-----	----------------	-------	-------	---------	----------	---------	------------	---------	----------------------	-----	----------	-------	--------------	-------	---------------	-------	-------------	--------	-------------------------	----------	-----------------------	----------	-------------------------------	----------	--	----------	-----------------------------	----------	-----------------------------	----------	-----------------	--------	---	--------	-------------------	----------	--------	----------	---------------------------	--------	------------------	--------	------------	-----

List of Tables Table 1:Symptoms of AD 30

Table 2:Guidelines for the Treatment of AD 37

Table 3:Most Prescribed Drugs for AD by Class in the Global Markets, 2012 38

Table 4:Leading Branded Treatments for AD, 2013 43

Table 5:Product Profile - Aricept 46

Table 6:Aricept SWOT Analysis, 2013 49

Table 7:Product Profile- Exelon 50

Table 8:Exelon SWOT Analysis, 2012 53

Table 9:Product Profile - Razadyne 55

Table 10:Razadyne SWOT Analysis, 2013 57

Table 11:Product Profile- Namenda 59

Table 12:Namenda SWOT Analysis, 2013 61

Table 13:Overall Unmet Needs - Current Level of Attainment 63

Table 14:Clinical Unmet Needs - Gap Analysis, 2013 70

Table 15:Technology Trends Analytic Framework for the AD Pipeline, 2012 80

Table 16:Comparison of Therapeutic Classes in Development for AD, 2013 80

Table 17:Comparison of Therapeutic Classes in Development for AD, 2013 81

Table 18:Sales Forecasts (\$m) for AD in China, 2012-2022 83

Table 19:Key Events Impacting Sales for AD in China, 2012-2022 85

Table 20:AD Market in China - Drivers and Barriers in China, 2012-2022 85

List of Figures Figure 1:Atrophy of the Brain in AD 19

Figure 2:Key Pathological Features in AD Versus a Healthy Neuron 21

Figure 3:Non-Amyloidogenic Metabolism of APP 23

Figure 4:Amyloidogenic Metabolism of APP 24

Figure 5:Neurofibrillary Tangles 26

Figure 6:Oxidative Damage Due to Free Radicals 28

Figure 7:Strategic Competitor Assessment of the Marketed Products in AD, 2013 44

Figure 8:AD - Pipeline Drugs by Target, 2012 74

Figure 9:Competitive Assessment of Late-Stage Pipeline Agents in AD, 2012-2022 81

Figure 10:Sales for AD in China by Drug Class, 2012-2022 84

To order this report: [PharmaPoint: Alzheimer's Disease - China Drug Forecast and Market Analysis to 2022](http://www.reportlinker.com/p01658537/PharmaPoint-Alzheimer's-Disease---China-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology)
http://www.reportlinker.com/p01658537/PharmaPoint-Alzheimer's-Disease---China-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Contact Clare: clare@reportlinker.com US:(339) 368 6001Intl:+1 339 368 6001

SOURCE Reportlinker

RELATED LINKS <http://www.reportlinker.com>